Table 4.
Predictive factors of NASH in non-tumoural parenchyma.
| Characteristics | NASH (N = 15) |
Total | P, univariate analysis | P, multivariate analysis | OR [95% CI] | |||
|---|---|---|---|---|---|---|---|---|
| Absent |
Present |
|||||||
| No. | % | No. | % | |||||
| Dyslipidaemia | ||||||||
| Yes | 29 | 78.4 | 8 | 21.6 | 37 | |||
| No | 101 | 93.5 | 7 | 6.5 | 108 | .02 | NR | |
| Diabetes | ||||||||
| Yes | 10 | 76.9 | 3 | 23.1 | 13 | |||
| No | 121 | 91.0 | 12 | 9.0 | 133 | .13 | ||
| Arterial hypertension | ||||||||
| Yes | 56 | 86.2 | 9 | 13.8 | 65 | |||
| No | 75 | 92.6 | 6 | 7.4 | 81 | .20 | ||
| Body mass index | ||||||||
| ⩽25 kg/m² | 70 | 97.2 | 2 | 2.8 | 72 | |||
| >25 kg/m² | 62 | 82.7 | 13 | 17.3 | 75 | .004 | .004 | 10.0 [2.1-47.5] |
| Chemotherapy with irinotecan | ||||||||
| Yes | 75 | 85.2 | 13 | 14.8 | 88 | |||
| No | 57 | 96.6 | 2 | 3.4 | 59 | .03 | .01 | 7.3 [1.5-34.7] |
| Chemotherapy with oxaliplatin | ||||||||
| Yes | 63 | 96.9 | 2 | 3.1 | 65 | |||
| No | 69 | 84.1 | 13 | 15.9 | 82 | .01 | ||
| Number of cycles | ||||||||
| ⩽8 | 67 | 88.2 | 9 | 11.8 | 76 | |||
| >8 | 65 | 91.5 | 6 | 8.5 | 71 | .50 | ||
| Pre-operative GGT | ||||||||
| ⩽1N | 67 | 93.1 | 5 | 6.9 | 72 | |||
| >1N | 49 | 86 | 8 | 14 | 57 | .045 | NR | |
| Pre-operative bilirubin | ||||||||
| ⩽1N | 89 | 93.7 | 6 | 6.3 | 95 | |||
| >1N | 8 | 80 | 2 | 20 | 10 | .033 | NR | |
Abbreviations: CI, confidence interval; GGT, gamma-glutamyltransferase; NASH, non-alcoholic steatohepatitis; NR, not retained at multivariate analysis; OR, odds ratio.